Recce Pharmaceuticals (ASX:RCE) has initiated a trading halt on its securities as of December 5, 2024. The halt precedes a significant announcement regarding the approval of their Registrational Phase 3 Diabetic Foot Ulcer Infection study. Trading will resume either upon the announcement or on December 9, 2024.
Recce Pharmaceuticals has requested a trading halt on the ASX to prepare for a pivotal announcement related to their Phase 3 Diabetic Foot Ulcer Infection study. The trading halt, effective from December 5, 2024, will last until the announcement is made or until December 9, 2024. This measure ensures that all market participants receive the material information simultaneously. Recce Pharmaceuticals is compliant with ASX Listing Rule 17.1 and is prepared for potential significant developments following the anticipated announcement.
The company is not aware of any reasons why the trading halt should not be granted. We have ensured that the market is informed about the trading halt through this announcement.